Skip to main content
. 2020 Sep 29;11(39):3571–3581. doi: 10.18632/oncotarget.27731

Figure 3. Treatment with 131I-labeled anti-CD45 30F11 antibody transiently depletes CD45-expressing immune cell subsets.

Figure 3

Treatment of non-tumor bearing C57B/6 mice with 3.7 MBq 131I-30F11 antibody was effective in transiently lymphodepleting various lymphocyte populations such as WBC, CD4+ cells, CD8+ cells, splenocytes, B cells, MDSC, NK cells, neutrophils and Tregs at a dose that does not impact bone marrow HSCs. Asterisks signify P values < 0.05.